The DEA’s Shift on Marijuana: What You Need to Know
| thcscout | Legalization | No Comments on The DEA’s Shift on Marijuana: What You Need to Know
Share
- No bookmark found
He highlights proposed government findings that most marijuana use does not endanger users or communities, that public health risks are lower than comparators like heroin, codeine, and oxycodone, and that HHS found sufficient scientific support for currently accepted medical use for chronic pain, anorexia associated with a medical condition, and chemotherapy-related nausea and vomiting—only one condition being necessary to leave Schedule I.
He discusses OLC’s conclusion that DEA’s prior CAMU test was impermissibly narrow, explains deference to HHS, notes DOJ’s unusual split scheduling of certain state-licensed/FDA-related products, and outlines next steps: the ALJ’s recommended decision followed by the DEA Administrator’s final order and Federal Register publication, with Howard predicting political pressure to finish before the midterms.
Subscribe for weekly historical breakdowns, and comment below with which major event you want me to cover next.
00:00 Yorktown Upside Down
00:33 DEA Brief Bombshell
01:48 Schedule One Basics
03:09 Risk Evidence Shift
04:41 Medical Use Concedes
06:51 OLC Narrows DEA Test
08:17 Weird Split Scheduling
10:38 Closing Argument Quote
11:35 What Happens Next
11:51 Timeline And Midterms
12:19 Federal Register Rule
13:08 Wrap Up And Call











